A message from our parters at SmallCaps Daily 
NV-387 by NanoViricides: A Revolutionary Therapy to Prevent Cancer Recurrence While Battling Deadly Viruses—Phase II Trials Underway! NanoViricides, Inc. (NYSE American: NNVC) is on the brink of a medical breakthrough with its lead compound, NV-387. Now advancing into Phase II clinical trials, NV-387 isn't just a powerful broad-spectrum antiviral—it may also stop dormant cancer cells from reawakening and driving metastasis. Research shows that infections like COVID-19, influenza, RSV and measles can trigger the return of metastatic cancer. NV-387 tackles this threat on two fronts: - Neutralizing a wide range of viruses
- Reducing harmful inflammation, particularly IL-6 cytokines linked to cancer cell reactivation
In preclinical studies, NV-387 protected lungs from lethal viral challenges and slashed inflammatory markers, outperforming antivirals such as Tamiflu and Xofluza. This first-in-class therapy combines lifesaving antiviral action with groundbreaking cancer-prevention potential. The global rise in viral infections and the lack of treatments addressing both viruses and metastatic recurrence create a significant unmet need. NV-387's exclusive nanoviricide™ platform ensures viruses can't escape—even as new variants emerge—giving NanoViricides a rare competitive advantage. With Phase II trials on the horizon, the clinical, commercial and societal impact of NV-387 could be extraordinary. Discover how NV-387's dual mechanism and unmatched preclinical data position NanoViricides to deliver transformative results—both medically and financially. | 
